Paper · 40454643

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.

Janjigian YY and 27 others. N Engl J Med, 2025. Cited by 276 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. Papers, record 40454643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40454643

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.; PubMed
Journal: N Engl J Med; PubMed
Year: 2025; PubMed
Publication types: Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/40454643/; PubMed
DOI: https://doi.org/10.1056/nejmoa2503701; PubMed
The journal: https://conductscience.org/library/journal-index/0255562; PubMed
Citations, by iCite: 276; iCite
Relative citation ratio, by iCite: 72.12, provisional; iCite
Revised in PubMed: 2025-10-22; PubMed

Authors28

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Janjigian YY	Yelena Y
2	Al-Batran SE	Salah-Eddin
3	Wainberg ZA	Zev A
4	Muro K	Kei
5	Molena D	Daniela
6	Van Cutsem E	Eric
7	Hyung WJ	Woo Jin
8	Wyrwicz L	Lucjan
9	Oh DY	Do-Youn
10	Omori T	Takeshi

1 to 10 of 28Source PubMed

See all 28 authors

Topics24

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Adenocarcinoma	Major topic
Antibodies, Monoclonal	Major topic
Antineoplastic Combined Chemotherapy Protocols	Major topic
Esophageal Neoplasms	Major topic
Esophagogastric Junction	Major topic
Stomach Neoplasms	Major topic
Aged
Female
Humans
Male
Middle Aged
Antineoplastic Agents, Immunological
Chemotherapy, Adjuvant
Docetaxel
Double-Blind Method
Fluorouracil
Kaplan-Meier Estimate
Leucovorin
Neoadjuvant Therapy
Oxaliplatin
Perioperative Care
Treatment Outcome
Adult
Aged, 80 and over

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
Not applicable	AstraZeneca			PubMed

Source PubMed

Trials4

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record	Source
NCT04592913	Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer	Derived from the trial	Yes	ClinicalTrials.gov
NCT07692477	Molecular Characterization of Tumor-Microenvironment Interactions to Predict Drug Resistance in Gastric and GEJ Adenocarcinoma	Background		ClinicalTrials.gov
NCT07899775	Lymph Node Metastasis Pattern After Neoadjuvant Chemoimmunotherapy in LAGC	Results		ClinicalTrials.gov
NCT07933471	Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Background		ClinicalTrials.gov

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers	Source
Comment in	41,124,639	Perioperative Durvalumab in Gastric Cancer.	https://conductscience.org/library/papers/41124639	PubMed
Comment in	41,124,640	Perioperative Durvalumab in Gastric Cancer.	https://conductscience.org/library/papers/41124640	PubMed
Comment in	41,124,641	Perioperative Durvalumab in Gastric Cancer. Reply.	https://conductscience.org/library/papers/41124641	PubMed

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by215

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 276 citations.

PMID	Title	Journal	Year	In Papers	Source
42,955,495	Treatment Options After Recurrence Following Perioperative Durvalumab Plus FLOT for Gastric and Gastroesophageal Junction Adenocarcinoma: A Biology-First Sequencing Framework.	Curr Treat Options Oncol	2026	https://conductscience.org/library/papers/42955495	PubMed
42,953,524	Advances in immunotherapy for gastrointestinal malignancies.	Front Immunol	2026	https://conductscience.org/library/papers/42953524	PubMed
42,938,863	Immunoscore and Post-Neoadjuvant Pathological Features in Microsatellite-Stable Locally Advanced Gastric Cancer: A Retrospective Cohort Study.	Cancers (Basel)	2026	https://conductscience.org/library/papers/42938863	PubMed
42,927,580	Prognostic associations between patient-reported outcomes and progression-free and overall survival in advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 TAP score ≥ 5%: results from the RATIONALE-305 trial.	Qual Life Res	2026	https://conductscience.org/library/papers/42927580	PubMed
42,909,237	Visualizing the distribution of durvalumab targeting PD-L1 using quantitative fluorescence imaging in patients with esophageal cancer.	Theranostics	2026	https://conductscience.org/library/papers/42909237	PubMed
42,902,061	Safety and efficacy of neoadjuvant S-1 and oxaliplatin therapy for gastric cancer in the elderly: combined phase II trials of KSCC1601 and KSCC1801.	Int J Clin Oncol	2026	https://conductscience.org/library/papers/42902061	PubMed
42,901,719	Neutrophil-epithelial niches arrest B-cell maturation in dysfunctional tertiary lymphoid structures of gastric cancer neoadjuvant immunochemotherapy.	J Immunother Cancer	2026	https://conductscience.org/library/papers/42901719	PubMed
42,900,306	Neoadjuvant Therapy for Gastric Adenocarcinoma with Signet Ring Cells: A Systematic Review and Meta-Analysis.	J Gastrointest Cancer	2026	https://conductscience.org/library/papers/42900306	PubMed
42,881,852	Post-Treatment Surveillance to Detect Recurrent Disease in Esophagogastric Cancer: A Review of Current Practice and Future Perspectives.	J Clin Med	2026	https://conductscience.org/library/papers/42881852	PubMed
42,873,429	Where You Live and Where You Are Treated: Addressing Disparities in Esophageal Adenocarcinoma.	Ann Surg Oncol	2026	https://conductscience.org/library/papers/42873429	PubMed

1 to 10 of 215

See all 215 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs5

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
LEUCOVORIN	CHEMBL1679	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL1679	ChEMBL
FLUOROURACIL	CHEMBL185	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL185	ChEMBL
DURVALUMAB	CHEMBL3301587	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL3301587	ChEMBL
DOCETAXEL	CHEMBL3545252	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL3545252	ChEMBL
OXALIPLATIN	CHEMBL414804	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL414804	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40454643

GET https://conductscience.org/api/papers/v1/40454643/authors?page=2

API reference For AI assistants